BioStock: Updated data further bolsters Alligator’s mitazalimab

Lund-based Alligator Bioscience continue to strengthen the case for their phase II candidate mitazalimab. The stock jumped 67 per cent today after encouraging updated results from the trial evaluating mitazalimab in combination with mFOLFIRINOX.  

Read the full article at biostock.se:

https://www.biostock.se/en/2025/02/updated-data-further-bolsters-alligators-mitazalimab/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se